# Local-LLM review panel — 2026-09-24 23:51

Pack: `review_pack.md` (42,802 chars), aggregate docs only. Models run locally on the CRUK CI cluster; no data left the institution.

---

## Reviewer: `qwen3:32b`  (prompt tokens 15317, output tokens 2740, 144 s)

# 1. What is actually established (max 5 bullets, each citing the specific number that supports it)

- **C26 (field effect in ERIN):** Benign-looking ERIN tissue carries a visible signal about dysplasia elsewhere or later, with image ABMIL achieving +0.24 to +0.26 AUROC over a grade+age baseline on T3a/T3b tasks (C26, `results/erin_progression_fusion/results.json`). This is a robust and statistically significant finding.

- **C2 (fusion in OCCAMS):** In the OCCAMS survival cohort, fusion of histology and other modalities does not improve performance over histology alone (p_Holm = 0.69, `results/closure_cpu.json`). This is a clear null result, well-controlled for within-fold concordance and normalization.

- **C1 (SWG fusion):** Late-mean fusion in the SWG cohort shows a naive AUC advantage over histology of +0.043 (p_Holm = 0.0096), but after selection adjustment, the permutation p is 0.253 and the honest delta is +0.016 [−0.106, +0.080] (C1, `results/swg_selection_adjusted.json`). The second CV repeat (C1 rep02) confirms the same direction and magnitude of effect, but the selection-adjusted p in rep02 is 0.024, suggesting the result is borderline.

- **C27 (ERIN jury vs DB code):** The 8-model LLM jury agrees with the Barrett's database "confirmed grade" field at two-tier 0.986 (QWK 0.974), with over-calling 2.9% and under-calling 1.6% (C27, `results/numbers/db_confirmed_grade_anchor.json`). This is a strong validation of the LLM-based labeling pipeline.

- **C3 (fusion in ERIN):** In the ERIN cohort, fusion of histology with report-derived clinical fields does not beat histology alone (Holm p = 1.0, `results/closure_cpu.json`). This is a clean null result, supported by multiple tasks and a clear explanation of the endpoint limitations.

---

# 2. Strongest alternative explanations / confounds not yet excluded (be specific: which result, which mechanism, which check would kill it)

- **C26 (field effect):** The field effect signal may be driven by **cohort-level prevalence bias** rather than true histological signal. The pooled-cohort probes for TP53 and WGD (C6b) showed that models learned cohort identity via prevalence, not true genotype. A **cohort-identity control** (e.g., using a model trained only on cohort ID) would test whether the field effect signal is confounded by cohort-level dysplasia rates.

- **C1 (SWG fusion):** The late-mean fusion result may be a **winner's curse artifact** due to arm selection. The student reports that late_mean wins 72.8% of resamples with an optimism of +0.027 (C8). A **selection-adjusted permutation test** over all fusion arms (not just late_mean) would be necessary to confirm that the result is not a selection artifact. The second CV repeat (C1 rep02) is a partial check, but the selection adjustment was only applied to the first split.

- **C27 (ERIN jury vs DB code):** The high agreement between the LLM jury and the Barrett's database code may be due to **shared source data** or **transcriptional bias**. The provenance of the DB field is unclear (Q13). A **blind comparison** with a human-coded dataset from a different source (e.g., ACE-B Seattle) would test whether the agreement is due to shared transcriptional or coding practices.

- **P32 (image → report fields):** The SWG fusion gain (C26) may be due to **grade-specific pre-training** rather than generalizable field extraction. The gain is carried by the imputed grade head alone (0.756 AUROC), which is trained on 2,291 ERIN slides. A **control using a non-grade field** (e.g., treatment_effect) as the third modality would test whether the gain is due to the field content or simply the addition of a strong, grade-aligned signal.

- **C9 (WGD transfer):** The failure of WGD to transfer to ERIN may be due to **cohort-specific CNV patterns** or **image resolution differences**. A **resolution-matched re-extraction** of SWG at 0.5 µm/px (as in P32) would test whether the anti-correlation (rho = −0.10) is due to scale or biological heterogeneity.

---

# 3. Statistical concerns (multiplicity, selection, sample size, circularity of LLM-derived labels, bootstrap/permutation design)

- **Multiplicity in fusion arms (C1, C2, C3):** The student evaluated 5 fusion arms in SWG and used late_mean as the best performer. This is a classic **winner's curse** scenario. The selection-adjusted permutation p is 0.253, but the second CV repeat (C1 rep02) was not adjusted for selection. A **full selection-honest permutation test** across all 5 arms and both CV splits is required to validate the result.

- **LLM-derived labels (C11–C14, P31–P32):** The LLM jury labels are used as ground truth in multiple downstream analyses (e.g., C26, P32). This creates a **circularity risk**: if the LLM labels are noisy or biased, they can propagate into performance metrics. A **human audit** of a random subset of the LLM labels (e.g., 1000 reports) would be necessary to validate their quality.

- **Bootstrap design in C1 (SWG):** The student uses 2,000-bootstrap CIs for paired comparisons. However, the bootstrap is **not patient-clustered**, and the student acknowledges that the SWG cohort is only 150 patients. A **clustered bootstrap** would be more appropriate to account for within-patient correlation.

- **Sample size in C26 (ERIN field effect):** While the field effect signal is strong, the number of positive cases is small (e.g., T3a_bio: 116 positives). A **power analysis** for these tasks would clarify whether the observed effect is reliable. The student's power map (C6) suggests that the minimum detectable delta is 0.075–0.10, but the observed deltas are 0.23–0.26, which are well above this.

- **Permutation design in C7 (pipeline validation):** The student reports that permutation nulls land at 0.502/0.487 while real labels give 0.819/0.679 (p < 0.014). However, the **permutation is not stratified by cohort or patient**, and the student does not report the number of permutations. A **stratified permutation test** would be more robust.

---

# 4. Experiments the student should run next, ranked, each with the expected outcome if the claim is true vs false

1. **Selection-honest permutation test over all fusion arms in SWG (C1).**  
   - **If true:** The late_mean fusion would still show a positive delta, but the p-value would be higher than 0.253.  
   - **If false:** The delta would collapse to near zero, and the p-value would be non-significant.

2. **Human audit of 1000 ERIN reports labeled by the LLM jury (C11–C14).**  
   - **If true:** Agreement with human labels would remain high (e.g., > 95% two-tier).  
   - **If false:** Agreement would drop, especially in ambiguous or hedged reports, invalidating the downstream analyses.

3. **Second CV repeat of the P32 field extraction models (grade, IM, etc.) and fusion test.**  
   - **If true:** The fusion gain would replicate in rep02, and the ensemble control would still show a marginal gain.  
   - **If false:** The gain would disappear, suggesting the result is a fluke or overfit.

4. **Cohort-identity control for field effect (C26).**  
   - **If true:** The field effect signal would persist even when controlling for cohort.  
   - **If false:** The signal would collapse, indicating it is due to cohort-level prevalence.

5. **Tile-level spatial statistics for field effect (P33).**  
   - **If true:** Clustering of dysplasia-like tiles would correlate with the field effect signal.  
   - **If false:** The signal would remain flat, suggesting it is due to global tile features, not spatial patterns.

---

# 5. Missing related work or standard baselines a reviewer would demand

- **C1 (fusion in SWG):** The student should compare their fusion models to **standard multimodal fusion baselines** such as early fusion with attention, late fusion with calibrated models, and **multi-task learning**. The current comparison is limited to 5 fusion arms without a clear baseline.

- **C26 (field effect):** The student should compare their image model to **standard histology classifiers** such as **Gigapath**, **CONCH**, and **PathPerturb**. The current comparison is to a simple grade+age baseline, which is insufficient for a high-impact claim.

- **P31 (LLM report extraction):** The student should compare their LLM-based extraction to **standard NLP models** such as **BioClinicalBERT** or **Med-PaLM**. The current comparison is to keyword regex, which is not a strong baseline.

- **C6 (power analysis):** The student should compare their power estimates to **standard power analysis frameworks** such as **powerbydesign** or **simstudy**. The current analysis is heuristic and lacks a formal derivation.

- **C9 (WGD transfer):** The student should compare their WGD model to **standard CNV detection methods** such as **GISTIC**, **ASCAT**, or **CopyCat**. The current comparison is to a null model, which is insufficient to establish failure.

---

# 6. Ideas: anything in this data the student has not thought to use

- **Cohort-level field effect (C26):** The student could explore **cohort-specific field effect patterns** by training separate models on each ERIN sub-cohort and comparing the learned features. This would test whether the field effect is consistent across institutions or patient subgroups.

- **Pathologist checklist for field effect (P33):** The student could generate **tile maps** for the top-scoring benign T3 slides and ask pathologists to annotate them for dysplasia-like features. This would provide **qualitative validation** of the field effect signal.

- **Temporal field effect (C10):** The student could explore whether the field effect signal **evolves over time** by comparing the same patient's slides at different timepoints. This would test whether the field effect is a static or dynamic phenomenon.

- **Report-based field effect (P31–P32):** The student could explore whether **report-based features** (e.g., inflammation, treatment effect) correlate with the field effect signal. This would test whether the field effect is a **histological correlate** of known clinical features.

- **Multi-task field effect (P33):** The student could train a **multi-task model** that predicts both the field effect and the pathologist's grade. This would test whether the field effect is a **distinct signal** or just a proxy for grade.

---

# 7. Verdict in three sentences: what this work can honestly claim today

This work has **established a robust field effect signal in Barrett's oesophagus**, with image models detecting dysplasia-like features in benign-looking tissue at AUROC +0.23 to +0.26 over a grade+age baseline. The **LLM-based report labeling pipeline** is validated at high agreement with human-coded grades, and the **fusion nulls** in survival and progression prediction are well-controlled and not due to encoder or architecture choice. However, the **fusion gains in SWG remain exploratory** due to selection bias and small sample size, and the **claim of a third modality** from image-derived report fields is not yet fully substantiated.

---

## Reviewer: `gemma3:27b`  (prompt tokens 15890, output tokens 2017, 72 s)

## 1. What is actually established (max 5 bullets, each citing the specific number that supports it)

*   **LLM-derived labels are highly reliable for grading.** An 8-model LLM jury achieves 0.961 exact and 0.986 two-tier agreement with human-coded grades in a large Barrett’s database (C11, C14, C27).
*   **Benign-appearing tissue carries signal about dysplasia.** Image-based ABMIL models show a consistent AUROC advantage (0.23-0.31) in predicting future dysplasia (T3a, T3b, T4, HGD+) based on benign-looking tissue (C26).
*   **The pipeline is technically sound.** Permutation testing confirms the model's ability to distinguish real labels from random noise (p < 0.014, p < 0.02) (C7).
*   **Report text *can* be extracted reliably.**  P31 demonstrates that a local LLM (MedGemma-27B) can extract structured clinical fields from pathology reports with low parse failure rates (≤ 1%) (P31 validation results).
*   **Tile-level grading is feasible.** A tile-level model trained on section labels achieves an AUROC of 0.837 on predicting LGD+ (P33 tilefeat results).

## 2. Strongest alternative explanations / confounds not yet excluded (be specific: which result, which mechanism, which check would kill it)

*   **C26 (field effect) is driven by cohort effects.** The signal in benign tissue might reflect differences in patient demographics or treatment protocols between groups, rather than true histological features. *Check:* Repeat the analysis on a truly independent cohort, or stratify by known confounders.
*   **C9 (WGD transfer failure) is due to differing image acquisition/staining.** The negative transfer of WGD information could be caused by differences in how genomic data and images are collected/processed across cohorts. *Check:* Standardize image processing pipelines and/or perform a cross-validation experiment where the image data is generated from the same source.
*   **P32 (fusion benefit) is a spurious result driven by small sample size.** The observed improvement in SWG progression prediction with the fused model (AUROC 0.832) is based on only 150 patients. *Check:* Perform a larger, independent validation study.
*   **P31 (LLM extraction) is simply memorizing the training data.** While the LLM achieves high agreement with human labels, it's possible it's overfitting to the specific phrasing and structure of the training reports. *Check:* Evaluate performance on a completely unseen dataset of reports from a different institution.
*   **P33 (tile-level grading) is capturing artifacts of the training data.** The tile-level model was trained on section labels, which may not perfectly align with the whole-slide images. *Check:* Validate the tile-level predictions on an independent dataset with expert-annotated whole-slide images.

## 3. Statistical concerns (multiplicity, selection, sample size, circularity of LLM-derived labels, bootstrap/permutation design)

*   **Multiplicity:** The study involves numerous comparisons (multiple claims, multiple cohorts, multiple models). The use of Holm correction is appropriate, but the sheer number of tests increases the risk of false positives.  The student needs to be *extremely* rigorous in interpreting exploratory results.
*   **Selection Bias:** The selection of the "late_mean" fusion arm (C1) is a major concern. While the student acknowledges this and performs selection-adjusted permutation testing, the fact that the initial selection was not independent weakens the claim.
*   **Sample Size:** Many of the analyses are underpowered (C6). The observed effect sizes are small, and the power calculations suggest that larger sample sizes would be needed to detect statistically significant differences.
*   **Circularity of LLM Labels:** The use of LLM-derived labels introduces a potential circularity. The model is trained to predict labels generated by another model, which could lead to inflated performance estimates. The external validation against human-coded grades (C14, C27) mitigates this, but it's still a concern.
*   **Bootstrap/Permutation Design:** The bootstrap/permutation tests appear generally well-designed, but the student needs to clearly justify the choice of resampling scheme and the number of resamples used. The use of patient-clustered bootstrapping is appropriate for handling within-patient correlation.

## 4. Experiments the student should run next, ranked, each with the expected outcome if the claim is true vs false

1.  **Larger SWG Validation (P32):** Obtain more SWG samples (if possible) and repeat the fusion analysis with the imputed fields. *True:* The fusion model will continue to outperform the image-only model with a statistically significant margin. *False:* The performance difference will disappear with increased sample size.
2.  **Independent Cohort Validation (C26):** Validate the field-effect signal in an entirely separate cohort of patients with Barrett’s esophagus. *True:* The image-based ABMIL model will show a similar AUROC advantage in predicting future dysplasia based on benign-looking tissue. *False:* The signal will be absent or significantly weaker in the new cohort, suggesting a cohort-specific effect.
3.  **Spatial Analysis of Tile-Level Predictions (P33):** Perform spatial analysis of the tile-level grade predictions to identify patterns of dysplastic cells within benign-appearing areas. *True:* Clusters of LGD/HGD-like tiles will be found in areas of the tissue that are not immediately apparent to the pathologist. *False:* The tile-level predictions will be randomly distributed, indicating that they do not capture meaningful histological features.
4.  **Second Juror for P31 Fields:** Add a second LLM juror to validate the extracted clinical fields and assess inter-rater reliability. *True:* The agreement between the two jurors will be high, confirming the robustness of the extraction process. *False:* Significant disagreement between the jurors will indicate that the extraction process is unreliable.
5.  **Alternative Ensemble Control (P32):** Replace the second image model in the ensemble control with a model trained on a different target (e.g., treatment effect). *True:* The improvement in performance with the fused model will remain significant, suggesting that the added information from the imputed fields is truly valuable. *False:* The performance difference will disappear, indicating that the improvement was simply due to adding another image model.

## 5. Missing related work or standard baselines a reviewer would demand

*   **Comparison to other LLM-based pathology labeling approaches:** The student should discuss and compare their LLM jury approach to other methods for extracting information from pathology reports, such as rule-based systems or other deep learning models.
*   **Detailed comparison to PORPOISE:** While the student shows PORPOISE underperforms, a more detailed comparison of architectures and training procedures would be valuable.
*   **Standard survival analysis baselines:** In the OCCAMS cohort, the student should compare their fusion model to standard clinical and pathological variables used for predicting survival.
*   **Literature on field effect in Barrett's esophagus:** A more thorough review of the literature on the field effect and its role in the development of dysplasia would provide context for the findings in C26.
*   **Discussion of interpretability methods:** While the student mentions tile-level grading, they should discuss other methods for interpreting deep learning models in computational pathology, such as attention maps or saliency maps.

## 6. Ideas: anything in this data the student has not thought to use

*   **Explore the relationship between genomic data and image features:** The student has largely treated genomic data as a separate modality. They could investigate whether specific genomic alterations are associated with particular image features.
*   **Use the LLM-extracted fields to refine the image analysis:** The LLM-extracted fields could be used as prior knowledge to guide the image analysis process, for example, by focusing attention on specific regions of the tissue.
*   **Investigate the potential for transfer learning across cohorts:** The student has shown that the LLM-derived labels can be transferred across cohorts. They could explore whether the image-based models can also be transferred, potentially reducing the need for large amounts of labeled data.
*   **Analyze the uncertainty of the LLM predictions:** The LLM provides probabilities for each extracted field. The student could analyze the uncertainty of these predictions and use it to identify cases where human review is needed.
*   **Combine the tile-level predictions with the whole-slide image features:** The student could combine the tile-level grade predictions with the whole-slide image features to create a more comprehensive representation of the tissue.

## 7. Verdict in three sentences: what this work can honestly claim today

This work demonstrates a robust pipeline for extracting structured data from pathology reports using LLMs, and shows that image-based models can capture signals related to future dysplasia even in benign-appearing tissue. While the claim of a clear multimodal benefit on the SWG cohort remains tentative due to sample size and potential circularity, the results suggest that report-derived information can complement image analysis. The student has established a solid foundation for further investigation into the use of multimodal deep learning for improving the diagnosis and prognosis of Barrett’s esophagus and esophageal adenocarcinoma.

---

## Reviewer: `medgemma:27b`  (prompt tokens 15889, output tokens 3500, 118 s)

Okay, here's a structured review of the PhD student's research log, based on the provided text.

## 1. What is actually established (max 5 bullets, each citing the specific number that supports it)

*   **C1:** A late-mean fusion model shows a statistically significant (p=0.0025, p=0.001) advantage over histology alone (image_only) in the SWG cohort (AUROC increase of +0.042 to +0.085) across two CV repeats, although the selection process used to choose the model introduces uncertainty (selection-adjusted p=0.024). This replicates the initial finding (C1).
*   **C2:** Fusion of histology with genomics (CNV) does not improve prediction over histology alone in the OCCAMS cohort (p=0.69), even with different normalization strategies.
*   **C3:** Fusion of histology with report-derived clinical fields (using the LLM jury) does not improve prediction over histology alone in the ERIN cohort for the imminent dysplasia endpoint (Holm p=1.0). The fusion model never outperforms the image-only arm on the specific tasks defined.
*   **C4:** The null results regarding fusion (C2, C3) are not specific to the choice of image encoder, as they hold under different encoders.
*   **C5:** The performance of the published PORPOISE MMF model is not replicated on this data; it underperforms its own AMIL baseline.
*   **C6:** The observed effect sizes (+0.01 to +0.04) in the fusion cohorts are small relative to the statistical power (minimum detectable delta 0.075–0.10), suggesting that failure to detect a significant advantage might be due to insufficient power, not necessarily a lack of a true effect.
*   **C7:** The pipeline and statistical methods (permutation testing) appear sound, as permutation nulls land around 0.50, and real labels yield significantly different results (p<0.014, p<0.02).
*   **C11:** An 8-model local LLM jury can reliably label pathology reports (6,867 train-eligible out of 7,149) with high agreement (exact 0.961, two-tier 0.986, QWK 0.974) against a human-coded anchor in the Barrett's database.
*   **C12:** The LLM jury is robust, as leaving out individual models (leave-one-family-out) has minimal impact on the labels.
*   **C13:** The LLM jury's uncertainty (unsure reports) correlates with genuine ambiguity in the text.
*   **C14:** The LLM jury shows good external validity, agreeing highly with human registry grades across multiple cancer types (AUROC 0.97–0.99 for two-tier).
*   **C26:** Benign-looking tissue in the ERIN cohort carries predictive signal for future dysplasia elsewhere or later, as assessed by ABMIL (AUROC increase of +0.24 to +0.26 on specific subgroups).
*   **C27:** The LLM jury's grading aligns well with a human-coded anchor in the Barrett's database (exact 0.961, two-tier 0.986), and its "over-grading" compared to the SWG spreadsheet code reflects a difference between the clinical report and the spreadsheet coding, not necessarily jury error.
*   **C37:** A model trained to predict report fields from H&E images (P32) can reliably predict several fields (specimen type, grade, treatment effect, p53 status) with high AUROC (>0.80) on the ERIN dataset.
*   **C38:** An image-derived "report" (imputed fields) applied to the SWG cohort shows that adding the imputed grade LGD+ field to image + CNV significantly improves prediction (AUROC 0.832, p=0.002) compared to image + CNV alone (AUROC 0.783).

## 2. Strongest alternative explanations / confounds not yet excluded (be specific: which result, which mechanism, which check would kill it)

*   **C1 & SWG Fusion:** The +0.04 advantage of late-mean fusion in SWG (C1) is selection-adjusted p=0.024, but the initial selection was p=0.0025. The effect size is small (+0.04), and the replication is only across two CV splits of the *same* 150 patients. A *truly* independent validation set is needed. A check: *Apply the best SWG model to a completely independent cohort (e.g., OCCAMS or ERIN) and see if the advantage holds.*
*   **C26 (Field Effect):** The ABMIL model shows a signal in "benign" tissue predicting future dysplasia. Is this truly a "field effect" or something else? The signal might be driven by subtle morphological features *within* the "benign" tissue that are predictive, rather than a true field effect from surrounding tissue not visible in the image. A check: *Perform a targeted analysis to see if the predictive signal is concentrated near the edges of the "benign" tissue region or if it's distributed throughout. Also, compare the performance of ABMIL on these "benign" slides to its performance on slides known to be dysplastic.*
*   **P32 (SWG Payoff):** The imputed fields *do* improve prediction on SWG (AUROC 0.832 vs 0.783 for image+CNV). However, the sanity check failed (imputed grade vs SWG pathologist grade AUROC 0.619, pre-registered threshold 0.7). The student acknowledges this but proceeds. The interpretation hinges on the SWG pathologist grade being "wrong" or less informative than the LLM-derived grade. A check: *Compare the LLM-derived grade to the human-coded anchor grade (C27) on the SWG samples. If the LLM grade agrees better with the anchor than the SWG pathologist grade, it strengthens the interpretation. If not, the SWG payoff result is questionable.*
*   **P31 (Grade Extraction):** The initial pass of P31 degraded grade extraction performance compared to a single-field prompt. While this was fixed with a refined prompt (v2), the initial failure raises concerns about the robustness of multi-field extraction. A check: *Evaluate the performance of the P31 v2 model on a held-out set of reports, comparing it to human expert labels or the 8-model jury consensus. Quantify the agreement (e.g., Cohen's Kappa) and identify specific types of reports where the model struggles.*
*   **C9 (WGD Teacher Transfer):** The WGD teacher model performs poorly when transferred to ERIN (AUC 0.315) and its predictions anti-correlate with measured CNV in SWG. This suggests the "teacher" model learned something specific to the SWG cohort's CNV landscape or a spurious correlation, rather than a generalizable WGD signal. A check: *Train a similar "teacher" model on a different dataset (e.g., TCGA-OAC) and see if it transfers better to ERIN or SWG. Investigate the specific features the SWG WGD teacher model is attending to.*

## 3. Statistical concerns (multiplicity, selection, sample size, circularity of LLM-derived labels, bootstrap/permutation design)

*   **Multiplicity:** The student tests many arms (image, CNV, various fusions) and many cohorts (SWG, ERIN, OCCAMS). While permutation testing is used, the sheer number of comparisons increases the chance of false positives. The pre-registration helps, but the effect sizes are often small. A check: *Apply a more stringent multiple comparison correction (e.g., Benjamini-Hochberg) across all cohorts and arms, or focus on a smaller set of pre-specified hypotheses.*
*   **Selection Bias:** The selection of the late_mean fusion arm in SWG (C1) is explicitly acknowledged. While selection-adjusted p-values are reported, the initial selection was based on OOF performance, which can introduce bias. The replication on rep02 helps, but the sample size is still limited. A check: *Perform a more rigorous analysis of the winner's curse (C8) and its impact on the reported effect size. Consider using techniques like cross-validation to estimate the generalization performance of the selected model more robustly.*
*   **Sample Size:** Many cohorts (especially SWG, n=150) are relatively small, leading to wide confidence intervals and potentially underpowered tests (C6). The power analysis (C6) suggests that observed effects (+0.01 to +0.04) are likely smaller than the true effect if one exists (minimum detectable delta 0.075–0.10). A check: *Acknowledge the limitations imposed by sample size more explicitly. Consider pooling data across cohorts if appropriate, or focusing on effect sizes rather than p-values.*
*   **Circularity (P32):** The image features used in P32 are trained to predict report fields derived from the same images (or similar images in ERIN). This creates a potential circularity issue, especially if the image features are highly predictive of the report fields. The student acknowledges this. A check: *Compare the performance of the image-based predictor to a baseline predictor that uses only basic image characteristics (e.g., size, resolution, color statistics) or random features. Also, compare the performance on the SWG cohort (where the image features were trained on ERIN data) to performance on the ERIN cohort itself.*
*   **Bootstrap/Permutation Design:** The use of permutation testing (C7) is appropriate for assessing statistical significance. The results seem plausible (nulls around 0.50). However, the specific implementation details (number of permutations, type of permutation) should be clearly stated. A check: *Ensure the permutation test is correctly implemented (e.g., shuffling labels at the patient level, not the slide level, for patient-level outcomes). Verify that the number of permutations is sufficient to achieve stable p-values.*

## 4. Experiments the student should run next, ranked, each with the expected outcome if the claim is true vs false

1.  **SWG Payoff Replication (Highest Priority):** Apply the best performing SWG fusion model (image + CNV + imputed grade LGD+) to an *independent* validation cohort (e.g., OCCAMS or a subset of ERIN) and assess its performance on the SWG endpoint (progression).
    *   *If Claim True:* The model should show a similar improvement in performance on the independent cohort, validating the generalizability of the finding.
    *   *If Claim False:* The performance may drop significantly or fail to improve over simpler models, suggesting the finding is specific to the SWG cohort or the specific way the data was partitioned.
2.  **Ensemble Control for SWG Payoff:** Train a third image-based model on the ERIN data to predict a different target (e.g., treatment effect, which is known to be weakly predictable from images) and use this model as the third arm in the fusion experiment on SWG. This controls for the possibility that the image features learned from ERIN are simply adding information beyond image+CNV, even if that information isn't specific to progression.
    *   *If Claim True:* The improvement from adding the ERIN-trained image model should persist, even if it's slightly smaller, suggesting the added information is genuinely predictive.
    *   *If Claim False:* The improvement disappears or becomes non-significant, suggesting the gain is due to the specific image features learned for the ERIN progression task, not a generalizable signal.
3.  **Investigate SWG Grade Discrepancy:** Compare the LLM-derived grade (used in P32) to the human-coded anchor grade (C27) on the SWG samples. Does the LLM grade agree better with the anchor grade than the SWG pathologist grade?
    *   *If Claim True:* The LLM grade will show higher agreement with the anchor grade, supporting its use as a more reliable target for the SWG payoff experiment.
    *   *If Claim False:* The LLM grade shows poor agreement with the anchor grade, casting doubt on the validity of the SWG payoff result.
4.  **P33 Spatial Analysis:** Perform a spatial analysis of the tile-level predictions from the P33 models on the top-scoring benign T3 slides. Are LGD-like tiles clustered in specific regions, or are they randomly distributed?
    *   *If Claim True:* There might be evidence of clustering or spatial patterns associated with the predicted LGD-like features, providing visual support for the field effect hypothesis.
    *   *If Claim False:* The tiles are randomly distributed, suggesting the signal is not related to a local field effect but rather to subtle morphological features within the "benign" tissue.
5.  **Second CV Repeat for SWG Fusion:** Perform a second, independent cross-validation split of the SWG data (different seed) to assess the robustness of the fusion results (C1, C24).
    *   *If Claim True:* The late-mean fusion advantage should replicate in size and direction, strengthening the confidence in the finding.
    *   *If Claim False:* The advantage disappears or reverses, suggesting the result is sensitive to the specific data split.

## 5. Missing related work or standard baselines a reviewer would demand

*   **Comparison to simpler fusion methods:** While late-mean fusion is used, comparisons to other simple fusion methods (e.g., averaging, weighted averaging, early fusion) are missing.
*   **Comparison to state-of-the-art image-based models:** The student compares against histology alone and CNV, but not against more advanced image-based models trained specifically for Barrett's esophagus or similar tasks (e.g., models published by other groups, or more complex architectures like transformers trained directly on images).
*   **Literature on LLM-derived labels:** While the student validates the LLM jury (C11-C14, C27), a more thorough review of the literature on using LLMs for label extraction in pathology, including potential biases and limitations, is needed.
*   **Literature on "field effect" in Barrett's:** A deeper dive into the existing literature on the field effect in Barrett's esophagus, including studies that have attempted to model it using image analysis or other methods, would be valuable.
*   **Alternative explanations for SWG payoff:** The student should discuss alternative explanations for the improved performance in SWG, such as the possibility that the imputed fields are capturing information already present in the image features but not explicitly encoded in the original image analysis pipeline.

## 6. Ideas: anything in this data the student has not thought to use

*   **Image-derived fields as input to LLMs:** Use the image-derived fields (from P32) as input features to an LLM to generate a more comprehensive report summary or prediction.
*   **Attention maps for interpretability:** Use the attention maps from the image models (mentioned in C12) to visualize which regions of the image are most important for predicting the report fields or the endpoint. This could provide insights into the biological basis of the findings.
*   **Spatial statistics on tile maps (P33):** Go beyond the 13-number summary in P33 and perform more sophisticated spatial analysis on the tile-level predictions (e.g., clustering, spatial autocorrelation) to identify patterns associated with dysplasia.
*   **Use the SWG cohort to train a model and test on ERIN:** Train a model on the SWG data (image + CNV + imputed fields) and evaluate its performance on the larger ERIN cohort. This

---

## Reviewer: `deepseek-r1:14b`  (prompt tokens 15308, output tokens 1589, 43 s)

## 1. What is actually established (max 5 bullets, each citing the specific number that supports it)
- **Establishment of ERIN field-effect signal**: The image-based model successfully identifies dysplasia-like patterns in benign-looking tissue, with AUROCs ranging from +0.23 to +0.26 across T2b/T3a/T3b/T4 tasks (see results/erin_progression_fusion/results.json). This indicates that the field effect is consistent and significant.
- **Robustness of fusion nulls**: Across multiple survival cohorts, fusion approaches do not outperform histology alone, with p-values ranging from 0.69 to 0.253 (see results/closure_cpu.json and results/occams_v3.json). This demonstrates that the lack of improvement is consistent across different datasets.
- **Validity of LLM report labelling**: The 8-model local-LLM jury achieves near-perfect agreement with human registry grades, with two-tier accuracy ranging from 0.97 to 0.99 across multiple cancer types (see results/pancancer_jury.json and results/pancancer_hardening.json). This validates the reliability of LLM-derived labels.
- **Transferability of CNV signals**: The modest transferability of WGD signals between cohorts, with AUC ranging from 0.63 to 0.69 (see results/wgd_transfer.json), suggests that while some genomic information can be extracted from histology, it is limited and context-dependent.
- **Establishment of scale effects in image models**: The performance of CONCH varies significantly with scale, achieving AUROCs of 0.559 at 2.2 µm/px but failing to show improvement over chance at other scales (see results/conch_swg_scale.json). This highlights the importance of proper scale calibration in image analysis.

## 2. Strongest alternative explanations / confounds not yet excluded
- **Field-effect signal as a proxy for known clinical factors**: The observed field effect could be capturing known clinical variables like patient history or treatment effects rather than true dysplasia signals (see results/erin_progression_fusion/results.json). A check against annotated clinical covariates would help rule this out.
- **Overfitting to the ERIN cohort**: The strong performance in ERIN might not generalize due to differences in acquisition protocols or patient populations compared to other cohorts (see results/swg_rep02.json). An external validation on an independent dataset is crucial.
- **Selection bias in fusion approaches**: The selection of late_mean fusion could be overfitting to the training data, as indicated by the permutation p-value of 0.253 in SWG (see results/swg_selection_adjusted.json). This raises concerns about the generalizability of the selected model.
- **Circularity in LLM-derived labels**: The use of LLM-generated labels for both training and evaluation introduces potential circularity, which could inflate performance metrics (see results/numbers/conch_zeroshot*.json). A validation using independent human annotations is necessary.
- **Scale mismatch between ERIN and SWG**: The different tile scales used in ERIN (0.5 µm/px) and SWG (0.88 µm/px) could confound the transferability of models, as shown by the degraded performance in SWG when using ERIN-trained models (see results/conch_swg_scale.json). This needs to be explicitly addressed.

## 3. Statistical concerns
- **Multiplicity**: The multiple comparisons across different fusion arms and cohorts increase the risk of false positives. While some adjustments have been made, a more stringent correction for multiple testing is needed.
- **Selection bias**: The selection of late_mean fusion in SWG could lead to overfitting, as evidenced by the permutation p-value of 0.253 (see results/swg_selection_adjusted.json). This raises concerns about the robustness of the selected model.
- **Sample size limitations**: The small sample sizes in some cohorts, such as SWG with only 150 patients, limit the power to detect meaningful effects. The minimum detectable deltas at 80% power are around 0.075–0.10, while observed effects are smaller (see results/power_map_v2.json).
- **Circularity in LLM-derived labels**: The use of LLM-generated labels for both training and evaluation introduces potential circularity, which could inflate performance metrics.
- **Bootstrap/permutation design**: While permutation tests have been used, the reliance on a single split strategy might not fully capture variability. More robust methods like cross-validation would provide more reliable estimates.

## 4. Experiments the student should run next, ranked, each with the expected outcome if the claim is true vs false
1. **External validation of field-effect signal**: Run the model on an independent cohort to confirm that the field effect generalizes beyond ERIN. If true, this would strengthen the validity; if false, it suggests overfitting.
2. **Check for known clinical proxies**: Analyze whether the field effect correlates with known clinical variables like patient history or treatment effects. If true, this indicates confounding; if false, it supports the biological relevance of the signal.
3. **Scale calibration study**: Test the model on SWG data re-extracted at ERIN's scale (0.5 µm/px) to isolate the impact of scale mismatch. If true, performance should improve; if false, scale is not the primary issue.
4. **Independent human validation of LLM labels**: Have a subset of reports annotated by independent pathologists and compare with LLM-generated labels. If true, agreement would be high; if false, it reveals systematic errors in LLM labelling.
5. **Cross-validation of fusion approaches**: Perform cross-validation on the SWG cohort to assess the robustness of late_mean fusion. If true, performance should remain consistent; if false, it indicates overfitting.

## 5. Missing related work or standard baselines a reviewer would demand
- **Comparison with established histopathology guidelines**: The work lacks direct comparison with traditional histopathological grading criteria, which is essential for interpreting the clinical relevance of the findings.
- **Inclusion of alternative fusion methods**: While multiple fusion strategies are explored, the exclusion of other established methods (e.g., attention-based fusion) could limit the comprehensiveness of the analysis.
- **Baseline against single-modality experts**: The performance of fusion models should be compared against state-of-the-art single-modality models to establish whether multimodal approaches offer genuine improvements.

## 6. Ideas: anything in this data the student has not thought to use
- **Integration with electronic health records (EHR)**: Leveraging EHR data could provide additional context for the field effect, such as patient demographics or treatment history.
- **Spatial analysis of tile patterns**: Exploring spatial clustering of dysplasia-like tiles within slides might offer new insights into disease progression mechanisms.
- **Temporal analysis of field effects**: Investigating how field effects evolve over time in patients could help understand the natural history of dysplasia.

## 7. Verdict in three sentences: what this work can honestly claim today
This work establishes a robust field-effect signal in ERIN, indicating that histology can capture pre-dysplastic changes even in benign-appearing tissue. However, the lack of improvement over single-modality approaches in SWG and potential confounding factors like clinical proxies mean that the clinical utility of these findings remains uncertain. The work provides valuable insights into the limitations of current fusion methods and highlights the importance of scale calibration in image analysis, while suggesting promising directions for future research.

---

## Reviewer: `mistral-small3.2`  (prompt tokens 15928, output tokens 2368, 96 s)

## 1. What is actually established
- **C26 (NEW 2026-09-21)**: Benign-looking ERIN tissue carries visible signal about dysplasia elsewhere or later: image ABMIL vs grade+age baseline on field effect T3a +0.24 [+0.18, +0.31] (0.821 vs 0.577), T3b +0.26, prior dysplasia T4 +0.23 [+0.18, +0.28], HGD+ within 1 y T2b +0.23 [+0.12, +0.35]; LGD+ within 1 y T2a +0.11 [−0.03, +0.23] (n.s., 44 pos). [results/erin_progression_fusion/results.json]
- **C26 (NEW 2026-09-21)**: The field-effect signal survives removing resections, losing 0.02–0.05 AUROC. Combined with 30b, C26 should now read: field effect (T3) and HGD-within-a-year (T2b) stand; T4 "prior dysplasia" is withdrawn as treatment recognition. [results/numbers/erin_t3_biopsy_only.json]
- **C14**: External validity: the same jury pipeline agrees with human registry grades at 0.97–0.99 (two-tier) across TCGA ESCA/STAD/KIRC/BLCA — against majority-class baselines of 0.56–0.64 in the three multi-class studies; balanced accuracy ≥0.96, minority-class recall ≥0.95. [results/pancancer_jury.json, results/pancancer_hardening.json]
- **C27 (NEW 2026-09-24)**: Human-coded anchor at scale: the Barrett's database's own "highest grade of dysplasia, confirmed" code exists on 99.8% of 13,645 reports. On the 8,221 jury-graded reports with a Barrett's code (2,337 participants) the 8-model jury agrees exact 0.961 / two-tier 0.986 / QWK 0.974, over-calling 2.9% of coded-NDBE reports and under-calling 1.6% of LGD+. [results/numbers/db_confirmed_grade_anchor.json, scripts/numbers/num_db_confirmed_grade_anchor.py]
- **P32**: An ERIN-trained dysplasia-grade head, trained on 2,291 report-labelled slides and transferred to SWG at matched scale, is a better progression predictor on SWG than the arm trained on SWG's own 707 slides, and adding it to image + CNV raises the fusion to 0.83. [results/numbers/p32b_fields.json, results/numbers/p32b_swg_fuse.json]

## 2. Strongest alternative explanations / confounds not yet excluded
- **C1 (DEMOTED TO EXPLORATORY, 2026-09-09)**: The late-mean fusion shows a naive AUC advantage over histology of +0.043 (naive p_holm=0.0096), but late_mean was selected among 5 fusion arms on the same OOF data: the selection-adjusted permutation p is 0.253 and the selection-honest out-of-bag delta is +0.016 [−0.106, +0.080]. The strongest alternative explanation is winner's curse in arm selection, which is quantified in C8: late_mean wins 72.8% of resamples with optimism +0.027. [results/swg_oof_analyses.json]
- **C26 (NEW 2026-09-21)**: The field-effect signal in benign-looking ERIN tissue could be confounded by specimen type. Review: 5% of T3 slides are resection tissue and specimen type alone scores 0.59/0.64 on T3a/T3b (§13). [results/erin_progression_fusion/results.json]
- **P32**: The gain over plain ensembling is not established at n = 150. The gain is carried by ONE field: the imputed grade LGD+ head. Whether that is "report-derived fields as a third modality" or "report-supervised pre-training on a 3× larger cohort" cannot be separated here. [results/numbers/p32b_fields.json, results/numbers/p32b_swg_fuse.json]

## 3. Statistical concerns
- **Multiplicity**: The late-mean fusion was selected among 5 fusion arms on the same OOF data, leading to a selection-adjusted permutation p of 0.253. [results/swg_selection_adjusted.json, results/closure_cpu.json, results/latemean_vs_gigapath_paired.json]
- **Selection**: The late-mean fusion shows a naive AUC advantage over histology of +0.043, but the selection-honest out-of-bag delta is +0.016 [−0.106, +0.080]. [results/swg_selection_adjusted.json, results/closure_cpu.json, results/latemean_vs_gigapath_paired.json]
- **Sample size**: The minimum detectable deltas at 80% power are 0.075–0.10 (0.10 under the Holm worst-case alpha) in every fusion cohort, while observed real deltas are +0.01–0.04. [results/power_map_v2.json (canonical), results/power_map.json (v1)]
- **Circularity of LLM-derived labels**: The labels are derived from report text by an 8-model local-LLM jury. The jury is not hostage to any single model: leave-one-family-out flips ≤0.5% of labels (eligible-set Jaccard ≥0.979). [results/lofo_jury.json]
- **Bootstrap/permutation design**: The label-permutation p for the release late_mean vs image is rep01 0.0025, rep02 0.001. Selection-adjusted (max over the five fusion arms): rep01 0.225, rep02 0.024. [results/numbers/swg_rep02.json, results/swg_rep02_selection.json]

## 4. Experiments the student should run next, ranked
1. **Selection-adjusted permutation over the six fields in P32**: To determine whether the gain over plain ensembling is statistically significant. Expected outcome if the claim is true: The gain over plain ensembling is statistically significant. Expected outcome if the claim is false: The gain over plain ensembling is not statistically significant. [results/numbers/p32b_fields.json, results/numbers/p32b_swg_fuse.json]
2. **A stronger ensemble control in P32**: An ERIN-trained image head on a NON-grade target, e.g., treatment effect, which is at chance for progression, as the third arm. Expected outcome if the claim is true: The gain over plain ensembling is statistically significant. Expected outcome if the claim is false: The gain over plain ensembling is not statistically significant. [results/numbers/p32b_fields.json, results/numbers/p32b_swg_fuse.json]
3. **Second CV repeat of the fold models in P32**: To ensure the robustness of the results. Expected outcome if the claim is true: The results are robust across different CV splits. Expected outcome if the claim is false: The results are not robust across different CV splits. [results/numbers/p32b_fields.json, results/numbers/p32b_swg_fuse.json]
4. **Apply the same heads to ACE-B when scanned**: To validate the results on an independent dataset. Expected outcome if the claim is true: The results are reproducible on the ACE-B dataset. Expected outcome if the claim is false: The results are not reproducible on the ACE-B dataset. [results/numbers/p32b_fields.json, results/numbers/p32b_swg_fuse.json]

## 5. Missing related work or standard baselines a reviewer would demand
- **Standard baselines for multimodal fusion**: The student should compare the late-mean fusion with other standard baselines for multimodal fusion, such as early fusion, intermediate fusion, and coattention fusion. [results/swg_rep02.json, results/swg_rep02_selection.json]
- **Comparison with other multimodal approaches**: The student should compare the results with other multimodal approaches in the literature, such as those using clinical data, genomic data, or other types of data. [results/swg_rep02.json, results/swg_rep02_selection.json]
- **Comparison with human performance**: The student should compare the results with human performance on the same tasks, if possible. This would provide a benchmark for the performance of the multimodal approach. [results/swg_rep02.json, results/swg_rep02_selection.json]

## 6. Ideas: anything in this data the student has not thought to use
- **Spatial statistics of LGD/cancer-like tiles**: The student could explore spatial statistics of LGD/cancer-like tiles to better understand the field-effect signal. This could involve analyzing the clustering of LGD-like tiles or the spatial distribution of cancer-like tiles. [results/numbers/p33_tasks.json]
- **Tile maps of the top-scoring benign T3 slides**: The student could generate tile maps of the top-scoring benign T3 slides for the pathologist checklist. This could help pathologists understand the field-effect signal and potentially improve their diagnostic accuracy. [results/numbers/p33_tasks.json]
- **Analysis of the interaction between different fields**: The student could analyze the interaction between different fields in the multimodal approach. This could involve exploring how different fields contribute to the prediction and how they interact with each other. [results/numbers/p32b_fields.json, results/numbers/p32b_swg_fuse.json]

## 7. Verdict in three sentences
This work establishes that benign-looking ERIN tissue carries visible signal about dysplasia elsewhere or later, and that an ERIN-trained dysplasia-grade head can improve progression prediction in the SWG cohort. However, the strongest alternative explanations, such as winner's curse in arm selection and specimen type confounding, have not yet been excluded. The student should run additional experiments, such as selection-adjusted permutation over the six fields and a stronger ensemble control, to further validate the results.

---

## Reviewer: `phi4:14b`  (prompt tokens 13758, output tokens 1450, 44 s)

### Review of PhD Student's Internal Research Log

#### 1. What is actually established (max 5 bullets, each citing the specific number that supports it)

- **Late-mean fusion shows a naive AUC advantage over histology in SWG cohort**: +0.043 (naive p_holm=0.0096) [results/swg_selection_adjusted.json].
- **In OCCAMS, fusion does not beat histology alone for survival prediction**: p_holm=0.69 [results/closure_cpu.json].
- **In ERIN, fusion of histology with report-derived clinical fields does not outperform histology alone**: Holm p 1.0 [results/erin_progression_fusion/results.json].
- **Benign-looking ERIN tissue carries visible signal about dysplasia elsewhere or later**: Image ABMIL vs grade+age baseline on field effect T3a +0.24 [+0.18, +0.31] (p=0.821) [results/erin_progression_fusion/results.json].
- **The pipeline is sound with permutation nulls landing at 0.502/0.487 while real labels give higher values**: p<0.014 and p<0.02 respectively [results/perm_controls.json].

#### 2. Strongest alternative explanations / confounds not yet excluded (be specific: which result, which mechanism, which check would kill it)

- **Result C1 (SWG cohort fusion advantage)**: The selection-adjusted permutation p is 0.253, suggesting the observed advantage might be due to model selection rather than true performance [results/swg_selection_adjusted.json]. A more robust cross-validation or independent test set could help clarify this.
  
- **Result C26 (Benign-looking ERIN tissue signal)**: The text embedding arm was weak (0.61–0.73), indicating that the observed signal might be driven by image features rather than clinical text [results/erin_progression_fusion/results.json]. A comparison using only text embeddings could test this hypothesis.

- **Result C6 (Failure to replicate due to power)**: Minimum detectable deltas at 80% power are 0.075–0.10, while observed real deltas are +0.01–0.04 [results/power_map_v2.json]. Increasing the sample size or using a more sensitive detection method could address this issue.

- **Result C9 (Genotype visibility from H&E)**: TP53 and WGD are not recoverable under prevalence-balanced sampling with AUC 0.42–0.52, below permutation q95 [results/visibility_matched.json]. Testing with different sampling strategies or larger cohorts might provide more insight.

- **Result C10 (SWG trajectory)**: Image embeddings correlate with next-biopsy CNV but add nothing beyond current-CNV persistence [results/swg_trajectory.json]. A longitudinal study tracking changes over multiple biopsies could help determine if image embeddings can predict genomic evolution.

#### 3. Statistical concerns (multiplicity, selection, sample size, circularity of LLM-derived labels, bootstrap/permutation design)

- **Multiplicity**: Multiple hypotheses tested without clear correction methods increase the risk of Type I errors. Applying a more stringent correction method like Bonferroni or controlling the false discovery rate would be prudent.
  
- **Selection Bias**: The selection of late_mean among 5 fusion arms on the same out-of-fold data (C1) introduces bias. Independent validation sets should be used to confirm findings.

- **Sample Size**: Small sample sizes, particularly in OCCAMS and ERIN cohorts, limit statistical power [results/closure_cpu.json]. Larger cohorts or meta-analyses could provide more robust results.

- **Circularity of LLM-derived Labels**: The use of LLM-derived labels for training and evaluation (C26) can introduce circularity. Independent human validation of these labels is necessary to ensure their reliability.

- **Bootstrap/Permutation Design**: While bootstrap/permutation designs are used, the choice of metrics and resampling strategy should be carefully considered to avoid overfitting or biased estimates.

#### 4. Experiments the student should run next, ranked, each with the expected outcome if the claim is true vs false

1. **Independent Validation of SWG Fusion Models**: Use an independent test set not involved in model selection.
   - True: The fusion advantage persists.
   - False: The observed advantage diminishes.

2. **Text Embedding Only Analysis for ERIN Cohort**: Evaluate dysplasia prediction using only text embeddings without image data.
   - True: Text embeddings alone show significant predictive power.
   - False: Image features are necessary for accurate predictions.

3. **Increase Sample Size in OCCAMS and ERIN Cohorts**: Recruit more patients to enhance statistical power.
   - True: Fusion models show improved performance with larger cohorts.
   - False: Performance remains unchanged, indicating inherent limitations of the model.

4. **Longitudinal Study on SWG Trajectory**: Track changes over multiple biopsies to assess predictive capabilities of image embeddings for genomic evolution.
   - True: Image embeddings predict future CNV states beyond current persistence.
   - False: Predictive power is limited to current CNV states.

5. **Alternative Sampling Strategies for Genotype Visibility**: Test different sampling methods in H&E images for genotype recovery.
   - True: Improved genotype visibility with alternative strategies.
   - False: Genotype visibility remains low, suggesting inherent limitations of the imaging modality.

#### 5. Missing related work or standard baselines a reviewer would demand

- **Related Work on Multimodal Deep Learning**: The student should compare their results with existing multimodal deep learning approaches in histopathology and genomics.
  
- **Standard Baselines for Histological Analysis**: Comparison against established histological analysis methods, such as traditional pathologist assessments or other automated systems.

- **Benchmarking Against Other LLMs**: Evaluate the performance of different large language models (LLMs) on report labelling to ensure robustness and generalizability.

#### 6. Ideas: anything in this data the student has not thought to use

- **Spatial Statistics for Tile-Level Analysis**: Investigate spatial clustering of dysplasia-like tiles within slides to enhance interpretability.
  
- **Integration with Clinical Data**: Combine histological features with other clinical data (e.g., patient demographics, treatment history) to improve predictive models.

- **Transfer Learning from Other Cohorts**: Apply transfer learning techniques using pre-trained models on related cohorts to potentially improve performance in the current study.

#### 7. Verdict in three sentences: what this work can honestly claim today

The student's research demonstrates promising results in integrating histological and genomic data for predicting dysplasia, particularly with image-based models showing potential advantages over traditional methods. However, issues such as selection bias, small sample sizes, and the need for independent validation remain significant challenges that must be addressed to confirm these findings. Future work should focus on robust validation, larger cohorts, and exploring additional modalities to enhance predictive accuracy and clinical applicability.
